I sistemi di controllo e la digital transformation: le sfide del middle management alla luce dei nuovi “topoi”

Endometriosis, a disease affecting 5-10% of women of reproductive age, is characterized by the spread of endometrial-like tissue outside the uterine cavity that produces ectopic endometriotic lesions causing pain and infertility [1].In this study, we investigated whether D-chiro inositol (DCI), a natural molecule known to affect ovarian steroidogenesis, may counteract the development of endometriotic lesions and improve therapeutic potential of conventional progestin drugs (i.e.Dienogest, DG).A mouse model of endometriosis was generated by intraperitoneal inoculation of endometrial tissue fragments in recipient CD1 mice, which were then treated for 28 days with: 0.4 mg DCI; 0.2 mg DCI+0.33 ng DG; or 0.67 ng DG, in drinking water; none (CTRL).Mice were then sacrificed and the intraperitoneal endometriotic lesions were excised.Numbers, extensions and vascularization degrees of endometriotic foci were reduced in all the treatment groups when compared to CTRL.The histological analysis revealed a marked reduction of endometriotic foci in all groups.To understand mechanisms underlying DCI effects, the expression of SIRT1, marker of epithelial-mesenchymal transition involved in endometriotic lesion development was evaluated [2].The analysis of SIRT1 transcripts highlight a decrease in the DCI+DG group compared to the CTRL; SIRT1 expression was not detected in the DCI group.The lesions were then subjected to immunohistochemical analysis aimed at evaluating the proliferative and vascularization status using PCNA and CD34, respectively.PCNA-positive epithelial and stromal cells were observed in the lesions; the DCI group showed a reduce expression of this marker.CD34 labeling showed similar levels in CTRL compared to DCI+DG and DG treated groups; the DCI group presents a reduction in the expression of this marker.CYP19A1 aromatase transcripts in the ovaries decreased in all groups.In conclusion, these observations make DCI a promising molecule for nutraceutical therapy of endometriosis.